ASGCT calls on every stakeholder examining proposed value-based models for transformational gene therapies to support the broadest possible patient access without limiting scientific innovation.
MILWAUKEE (PRWEB) May 15, 2018
In advance of the American Society of Gene & Cell Therapy's 21st Annual Meeting, May 16-19 at the Hilton Chicago, the Society has issued a white paper addressing the issues surrounding value and payment for new and incoming gene and cell therapies.
The value of gene therapy has become an increasingly prominent topic following the 2017 FDA approval of three gene therapies (including gene-modified cell therapies). Any discussion of the value of gene therapy must include the vast potential of these therapies to treat a variety of diseases, many of them rare disorders with great unmet need. ASGCT has therefore created a white paper, Addressing the Value of Gene Therapy: Enhancing Patient Access to Transformative Treatments.
The paper highlights the substantial value of gene therapy and the need to lower barriers between patients and access to approved therapies. ASGCT identifies priority solutions and recommends further exploration of additional means for stakeholders in the field to work toward maximizing the potential value of gene therapy through enhanced patient access.
About The American Society of Gene & Cell Therapy
ASGCT is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT’s vision is to serve as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.